EMBO Fellow at IannaconeLab | San Raffaele Scientific Institute
B & T cell immunologist 🔬
Poetry lover, kinda musician, WIP photographer, someday filmmaker ❤️🔥
Exploring the intersection of science, art, and humanity 🙂
World is for everyone! 🏳️🌈✊🏼
Cristian G Beccaria
Loading...
Excited to share our new work in @Science Translational Med! A collaborative effort exploring RNAi for silencing HBV antigens and rebalancing immunity in chronic hepatitis B.
I hope you enjoy it! and we’re always open to discuss perspectives! :)
Thrilled to share our latest publication 😃! Beyond the science and the new paths it opens, working with you @valentinavenzin.bsky.social has been one of the most beautiful and transformative journeys of my life. So proud of what we built together with the whole lab! Hope you enjoy it!
Thrilled to share some of the stories we've been working on in our @iannaconelab.bsky.social at #IUIS2025 @iuis-online.bsky.social in Vienna! Excited to chat with so many friends and colleagues from around the world! @davidemarotta.bsky.social @CaitlinAAbbott
Amazing talk by Michelle @linterman.bsky.social at @iuis-online.bsky.social 2025 on ageing and immune responses to vaccines, shedding light on how understanding these mechanisms can guide the development of better immunization strategies
One year under Milei, Argentina’s science faces collapse. Budget cuts, brain drain, and ideological censorship are dismantling a system that once thrived despite challenges. Researchers are leaving, projects are halted... Its so so sad
www.nature.com/articles/d41...
This is so awesome! Science’s Breakthrough of the Year, Lenacapavir, an injectable drug that prevents HIV infection for 6 months, shows up to 100% efficacy in trials. A game-changer in PrEP, powered by basic research on HIV. Next... ensuring access worldwide!
www.science.org/content/arti...
What can I say... my watercolor made it to the cover of the latest issue of @natimmunol.nature.com, together with our paper on IL-27 in chronic hep B 🚀 We really put the cherry on top in the @iannaconelab.bsky.social @cristianbeccaria.bsky.social. 🥹💜 Check it out! www.nature.com/ni/volumes/2...
So happy to share that our review in #ImmunolRev is finally out! 😃 We discuss how the immune system builds specialized TLSs across organs and conditions. Huge thanks to @StephanGuillaume, @iannaconelab.bsky.social & @linterman.bsky.social for this collaboration!
dx.doi.org/10.1111/imr.70063
If an #H5N1 pandemic starts tomorrow or in three months, there will be little mystery as to how it happened. The conditions are all there. They have been for a while.
So in some ways the more interesting question to me at the moment is: Why aren’t we in a pandemic yet?
Story here, 🧵 to come:
🧪#IDSky
Drs. @valentinavenzin.bsky.social, @cristianbeccaria.bsky.social, and the @iannaconelab.bsky.social identified the molecular and cellular mechanisms by which CD4⁺ #Tcells can restore antiviral CD8⁺ T cell function in the #liver.
@natimmunol.nature.com: go.nature.com/3Ggjajr
🎧: bit.ly/3GP9NaK
Tertiary lymphoid structures (TLSs) arise in non-lymphoid tissues in response to persistent antigen stimulation and chronic inflammation. Spanning organs from lung and liver to meninges, skin, and be...
A drug with a novel mechanism protects people against the AIDS virus for 6 months. It could speed the end of the epidemic—if those who need it most get access
www.science.org
One year into Javier Milei’s presidency, scientists are exiting the country in the face of big budget cuts.
Happy to share our latest review "Targeting HBV with RNA interference: Paths to cure"| Science Translational Medicine www.science.org/doi/10.1126/... written together with @cristianbeccaria.bsky.social, Lena Allweiss, Julie Lucifora, John Tavis, Adam Gehring and Maura Dandri
11/ Kudos to @valentinavenzin.bsky.social, @cristianbeccaria.bsky.social, all members of the @iannaconelab.bsky.social&collaborators for charting this intrahepatic circuit. Expect Kupffer cell licensing and IL 27 to enter conversations on cancer immunotherapy, vaccines and beyond. Thoughts welcome!
